TY - JOUR
T1 - Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline
AU - Galindo, Rodolfo J.
AU - Umpierrez, Guillermo E.
AU - Rushakoff, Robert J.
AU - Basu, Ananda
AU - Lohnes, Suzanne
AU - Nichols, James H.
AU - Spanakis, Elias K.
AU - Espinoza, Juan
AU - Palermo, Nadine E.
AU - Awadjie, Dessa Garnett
AU - Bak, Leigh
AU - Buckingham, Bruce
AU - Cook, Curtiss B.
AU - Freckmann, Guido
AU - Heinemann, Lutz
AU - Hovorka, Roman
AU - Mathioudakis, Nestoras
AU - Newman, Tonya
AU - O’Neal, David N.
AU - Rickert, Michaela
AU - Sacks, David B.
AU - Seley, Jane Jeffrie
AU - Wallia, Amisha
AU - Shang, Trisha
AU - Zhang, Jennifer Y.
AU - Han, Julia
AU - Klonoff, David C.
N1 - Publisher Copyright:
© 2020 Diabetes Technology Society.
PY - 2020
Y1 - 2020
N2 - This article is the work product of the Continuous Glucose Monitor and Automated Insulin Dosing Systems in the Hospital Consensus Guideline Panel, which was organized by Diabetes Technology Society and met virtually on April 23, 2020. The guideline panel consisted of 24 international experts in the use of continuous glucose monitors (CGMs) and automated insulin dosing (AID) systems representing adult endocrinology, pediatric endocrinology, obstetrics and gynecology, advanced practice nursing, diabetes care and education, clinical chemistry, bioengineering, and product liability law. The panelists reviewed the medical literature pertaining to five topics: (1) continuation of home CGMs after hospitalization, (2) initiation of CGMs in the hospital, (3) continuation of AID systems in the hospital, (4) logistics and hands-on care of hospitalized patients using CGMs and AID systems, and (5) data management of CGMs and AID systems in the hospital. The panelists then developed three types of recommendations for each topic, including clinical practice (to use the technology optimally), research (to improve the safety and effectiveness of the technology), and hospital policies (to build an environment for facilitating use of these devices) for each of the five topics. The panelists voted on 78 proposed recommendations. Based on the panel vote, 77 recommendations were classified as either strong or mild. One recommendation failed to reach consensus. Additional research is needed on CGMs and AID systems in the hospital setting regarding device accuracy, practices for deployment, data management, and achievable outcomes. This guideline is intended to support these technologies for the management of hospitalized patients with diabetes.
AB - This article is the work product of the Continuous Glucose Monitor and Automated Insulin Dosing Systems in the Hospital Consensus Guideline Panel, which was organized by Diabetes Technology Society and met virtually on April 23, 2020. The guideline panel consisted of 24 international experts in the use of continuous glucose monitors (CGMs) and automated insulin dosing (AID) systems representing adult endocrinology, pediatric endocrinology, obstetrics and gynecology, advanced practice nursing, diabetes care and education, clinical chemistry, bioengineering, and product liability law. The panelists reviewed the medical literature pertaining to five topics: (1) continuation of home CGMs after hospitalization, (2) initiation of CGMs in the hospital, (3) continuation of AID systems in the hospital, (4) logistics and hands-on care of hospitalized patients using CGMs and AID systems, and (5) data management of CGMs and AID systems in the hospital. The panelists then developed three types of recommendations for each topic, including clinical practice (to use the technology optimally), research (to improve the safety and effectiveness of the technology), and hospital policies (to build an environment for facilitating use of these devices) for each of the five topics. The panelists voted on 78 proposed recommendations. Based on the panel vote, 77 recommendations were classified as either strong or mild. One recommendation failed to reach consensus. Additional research is needed on CGMs and AID systems in the hospital setting regarding device accuracy, practices for deployment, data management, and achievable outcomes. This guideline is intended to support these technologies for the management of hospitalized patients with diabetes.
KW - COVID-19
KW - automated insulin dosing
KW - continuous glucose monitor
KW - guideline
KW - hospital
UR - http://www.scopus.com/inward/record.url?scp=85091686008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091686008&partnerID=8YFLogxK
U2 - 10.1177/1932296820954163
DO - 10.1177/1932296820954163
M3 - Article
C2 - 32985262
AN - SCOPUS:85091686008
SN - 1932-2968
VL - 14
SP - 1035
EP - 1064
JO - Journal of Diabetes Science and Technology
JF - Journal of Diabetes Science and Technology
IS - 6
ER -
